These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 34074937)
1. Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. Gerjevic KA; Ahmad S; Strohbehn K; Riblet N Female Pelvic Med Reconstr Surg; 2021 Aug; 27(8):481-487. PubMed ID: 34074937 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M Value Health; 2011; 14(2):219-28. PubMed ID: 21402292 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750 [TBL] [Abstract][Full Text] [Related]
4. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855 [TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Tay LJ; Harry D; Malde S; Sahai A Urology; 2021 Mar; 149():1-10. PubMed ID: 33227305 [TBL] [Abstract][Full Text] [Related]
6. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review. Zhang Y; Ji F; Liu E; Wen JG Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295 [TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. Autiero SW; Hallas N; Betts CD; Ockrim JL BJU Int; 2015 Dec; 116(6):945-54. PubMed ID: 25407358 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584 [TBL] [Abstract][Full Text] [Related]
10. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis. Yang G; Xu Y; Qu G; Zhang Y PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113 [TBL] [Abstract][Full Text] [Related]
12. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. He Q; Li B; Zhang C; Zhang J; Luo D; Wang K Int Urogynecol J; 2021 Mar; 32(3):477-484. PubMed ID: 32661556 [TBL] [Abstract][Full Text] [Related]
13. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658 [TBL] [Abstract][Full Text] [Related]
14. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519 [TBL] [Abstract][Full Text] [Related]
15. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost. Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective. Hassouna MM; Sadri H Can Urol Assoc J; 2015; 9(7-8):242-7. PubMed ID: 26316906 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of sequential third-line therapies in patients with refractory overactive bladder. Chow PM; Trump T; Goldman HB Int J Urol; 2024 Jul; 31(7):772-777. PubMed ID: 38693892 [TBL] [Abstract][Full Text] [Related]
18. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542 [TBL] [Abstract][Full Text] [Related]
19. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis. Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358 [TBL] [Abstract][Full Text] [Related]
20. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]